CYP24 splicing variants are associated with different patterns of constitutive and calcitriol-inducible CYP24 activity in human prostate cancer cell lines

Journal of Steroid Biochemistry and Molecular Biology

Volumn 103, Issue 3-5, 2007, Pages 334-337

  Muindi, Josephia R ^a   Nganga, Alain ^a   Engler, Kristie L ^a   Coignet, Lionel J ^a   Johnson, Candace S ^a   Trump, Donald L ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

CYP24 SNPs; Prostate cancer cell lines; Splicing and enzyme activity profile

Indexed keywords

CALCITRIOL; ENZYME; STEROID 24 HYDROXYLASE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL STRAIN LNCAP; CONTROLLED STUDY; ENZYME ACTIVITY; EXON; HUMAN; HUMAN CELL; INTRON; MALE; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM;

ALTERNATIVE SPLICING; CALCITRIOL; CELL LINE, TUMOR; ENZYME ACTIVATION; EXONS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; INTRONS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; STEROID HYDROXYLASES; VARIATION (GENETICS);

EID: 33947124593     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2006.12.060     Document Type: Article

References (12)

1. Ly L.H., Zhao X.Y., Holloway L., and Feldman D. Liarozole acts synergistically with 1alpha, 25- dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity. Endocrinol 5 (1999) 2071-2076
2. Miettinen S., Ahonen M.H., Lou Y.R., Manninen T., Tuohimaa P., Syvala H., and Ylikoma T. Role of 24-hydroxylase in Vitamin D3 growth response of OVCAR-3 ovarian cancer cells. Int J Cancer 108 (2004) 367-373
3. Masuda S., Byford V., Arabian A., Sakai Y., Demay M.B., St-Arnaud R., and Jones G. Altered pharmacokinetics of 1alpha, 25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 in the blood and tissues of the 25-hydroxyvitamin D-24-hydroxylase (CYP24A1) null mouse. Endocrinol 146 (2005) 825-834
4. 3 in seven human prostatic carcinoma cell lines. Clin Cancer Res 1 (1995) 997-1003
5. Jones G., Ramshaw H., Zhang A., Cook R., Byford V., White J., and Petkovich M. Expression and activity of Vitamin D-metabolizing cytochrome P450s (CYP1alpha and CYP24) in human nonsmall cell lung carcinomas. Endocrinology 140 (1999) 3303-3310
6. Mimori K., Tanaka Y., Yoshinaga K., Masuda T., Yamashita K., Okamoto M., Inoue H., and Mori M. Clinical significance of the overexpression of the candidate oncogene CYP24 in esophageal cancer. Ann Oncol. 15 (2004) 236-241
7. Albertson D.G., Mistral B., Segraves R., Collins C., Dairkee S.H., Kowbel D., Kuo W.L., Gray J.W., and Pinkel D. Quantitative mapping of amplicon structure by CGH identifies CYP24 as a candidate oncogene. Nat. Genet. 25 (2000) 144-146
8. Khorchide M., Lechner D., and Cross H.S. Epigenetic regulation of Vitamin D hydroxylase expression and activity in normal and malignant human prostate cells. J. Steroid Biochem. Mol. Biol. 93 (2005) 167-172
9. Kallay E., Bises G., Bajna E., Bieglmayer C., Gerdenitsch W., Steffan I., Kato S., Armbrecht H.J., and Cross H.S. Colon-specific regulation of Vitamin D hydroxylases-a possible approach for tumor prevention. Carcinogenesis 26 (2005) 1581-1589
10. 3 by phosphorylation of ferredoxin. Biochem. J. 266 (1990) 385-392
11. Ren S., Nguyen L., Wu S., Encina C., Adams J.S., and Hewison M. Alternative splicing of Vitamin D-24-hydroxylase: a novel mechanism for the regulation of extra-renal 1,25-dihydroxyvitamin D synthesis. J. Biol. Chem. 280 (2005) 20604-20611
12. Akeno N., Matsunuma A., Maeda T., Kawane T., and Horiuchi N. Regulation of Vitamin D-1alpha-hydroxylase and -24-hydroxylase expression by dexamethasone in mouse kidney. J. Endocrinol. 164 3 (2000) 339-348